# reload+after+2024-01-21 18:45:24.249948
address1§645 Summer Street
address2§Suite 101
city§Boston
state§MA
zip§02210
country§United States
phone§857 273 8343
website§https://ikenaoncology.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Ikena Oncology, Inc. operates as an oncology company that develops precision medicines to biomarker-defined patients with specific unmet needs in the United States. Its lead oncology product candidate is IK-930, a paralog selective inhibitor of the transcriptional enhanced associate domain, a transcription factor in the Hippo signaling pathway. It also develops IK-595, designed to trap MEK and RAF for inhibiting RAS signals than existing inhibitors; and IK-175, a monotherapy and in combination with nivolumab in patients with advanced or metastatic solid tumors, including urothelial carcinomas. Ikena Oncology, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
fullTimeEmployees§57
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Mark  Manfredi Ph.D.', 'age': 52, 'title': 'President, CEO & Director', 'yearBorn': 1971, 'fiscalYear': 2022, 'totalPay': 803900, 'exercisedValue': 0, 'unexercisedValue': 221063}, {'maxAge': 1, 'name': 'Dr. Jotin  Marango M.D., Ph.D.', 'age': 44, 'title': 'CFO & Head of Corporate Development', 'yearBorn': 1979, 'fiscalYear': 2022, 'totalPay': 581416, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Sergio L. Santillana M.B.A., M.D., M.Sc.', 'age': 60, 'title': 'Chief Medical Officer', 'yearBorn': 1963, 'fiscalYear': 2022, 'totalPay': 632178, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Bob  Lally', 'title': 'Senior Vice President of Finance & Operations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Michelle  Zhang Ph.D.', 'title': 'Chief Scientific Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Samantha  Vuksanic', 'title': 'Head of Human Resources', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Jeffrey  Ecsedy Ph.D.', 'age': 53, 'title': 'Chief Development Officer', 'yearBorn': 1970, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Alexander  Constan Ph.D.', 'title': 'Senior Vice President of Non Clinical Safety & DMPK', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Navin  Parwani M.S.', 'title': 'VP & Head of Quality', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Sabine  Ruppel Ph.D.', 'title': 'VP & Head of Discovery', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§8
boardRisk§8
compensationRisk§9
shareHolderRightsRisk§10
overallRisk§10
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§0.302
priceToSalesTrailing12Months§6.2955875
currency§USD
dateShortInterest§1702598400
forwardEps§-1.92
exchange§NGM
quoteType§EQUITY
shortName§Ikena Oncology, Inc.
longName§Ikena Oncology, Inc.
firstTradeDateEpochUtc§1616765400
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§91b1e3b2-6a3b-3cff-83da-6bebdfb084db
gmtOffSetMilliseconds§-18000000
targetHighPrice§11.0
targetLowPrice§6.0
targetMeanPrice§8.33
targetMedianPrice§8.0
recommendationMean§1.4
recommendationKey§strong_buy
numberOfAnalystOpinions§3
quickRatio§10.219
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
